Revive Therapeutics (RVVTF) Stock Research

Today

Revive Therapeutics reports results from DRDC bucillamine research study

7:57 AM

Over a week ago

Revive expands bucillamine program across infectious diseases

May 20, 7:51 AM

Revive Therapeutics announces North American patent filings for bucillamine

Mar 11, 7:37 AM

Revive Therapeutics provides update on nerve agent countmeasure study

Dec 15, 7:41 AM

Revive Therapeutics says nerve agent countmeasure study 'remains in progress'

Nov 21, 12:10 PM

No more stories